BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

EHA 2025

Multiple Myeloma (MM)

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

ASH 2025

Multiple Myeloma (MM)

DREAMM-7: Belantamab mafodotin combination achieves superior MRD outcomes in patients with RRMM

Multiple Myeloma (MM)

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma

Blood

Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, Spiliopoulou V, Migkou M, Fotiou DV, Theodorakakou F, Kastritis E, Gavriatopoulou M, Tsitsilonis O, Dimopoulos MA

doi: 10.1182/blood.2024027686

EHA 2025

Leukemia

Blinatumomab led to high remission and MRD negativity rates in routine clinical practice for adult Ph-negative B-cell ALL

SABCS 2025

Breast Cancer

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

Leukemia

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Ye Y, Labopin M, Yakoub-Agha I, Socié G, Blaise D, Gedde-Dahl T, Blau IW, Raiola AM, Byrne J, Daguindau E, Labussière-Wallet H, Huynh A, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Mohty M, Huang H, Ciceri F

doi: 10.1002/ajh.70008

ASH 2025

Multiple Myeloma (MM)

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

ASH 2025

Multiple Myeloma (MM)

Related content

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

DREAMM-7: Belantamab mafodotin combination achieves superior MRD outcomes in patients with RRMM

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma

Blinatumomab led to high remission and MRD negativity rates in routine clinical practice for adult Ph-negative B-cell ALL

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

CARTITUDE-4: Cilta-cel achieves sustained PFS and durable remissions in standard-risk RRMM

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM